Table 2.
Cell Lines | Origin | IFN-γ Dose | Treatment Time | Detection Method |
Effect on PD-L1 |
---|---|---|---|---|---|
BPH1 [13] | Human | 50 mg/mL | 24 h | WB | = |
CWR22Rv1 [94] | Human | 100 U/mL | 48 h | FC | ↑ |
CWRR-1 [13] | Human | 50 mg/mL | 24 h | WB | = |
C4-2 [13] | Human | 50 mg/mL | 24 h | WB | = |
DU145 [126] | Human | 0.5–10–20 ng/mL | 48 h | FC | = |
DU145 [10] | Human | Not reported | Not indicated | RT-PCR, FC | ↑ |
DU145 [94] | Human | 100 U/mL | 48 h | FC | ↑ |
DU145 [112] | Human | 10 ng/mL | 24 h | WB, FC | ↑ |
DU145 [119] | Human | 100 U/mL | 48 h | FC | ↑ |
DU145 [152] | Human | 10 ng | 24 h | FC | ↑ |
E006AA [94] | Human | 100 U/mL | 48 h | FC | ↑ |
LASCPC [13] | Human | 50 mg/mL | 24 h | WB | ↑ |
LAPC-4 [94] | Human | 100 U/mL | 48 h | FC | = |
LNCaP [13] | Human | 50 mg/mL | 24 h | WB | = |
LNCaP [94] | Human | 100 U/mL | 48 h | FC | = |
LNCaP [128] | Human | 10–100 ng/mL | 24 h | FC | = |
MyC-CaP [106] | Mouse | 0.1–1–10 ng/mL | 72 h | FC | ↑ |
NCI-H660 [13] | Human | 50 mg/mL | 24 h | WB | ↑ |
PC3 [10] | Human | Not reported | Not indicated | RT-PCR, FC | ↑ |
PC3 [13] | Human | 50 mg/mL | 24 h | WB | ↑ |
PC3 [94] | Human | 100 U/mL | 48 h | FC | ↑ |
PC3 [103] | Human | 20 ng/mL | 24 h | WB, FC | ↑ |
PC3 [112] | Human | 10 ng/mL | 24 h | WB, FC | ↑ |
PC3 [119] | Human | 100 U/mL | 48 h | FC | ↑ |
PC3 [128] | Human | 10–100 ng/mL | 24 h | FC | ↑ |
PC3 [139] | Human | 100 ng/mL | 24 h | RT-PCR, WB | ↑ |
PC3 [152] | Human | 10 ng | 24 h | FC | ↑ |
TRAMP-C1 [106] | Mouse | 0.1–1–10 ng/mL | 72 h | FC | ↑ |
TRAMP-C2 [126] | Mouse | 0.5–10–20 ng/mL | 48 h | FC | ↑ |
TRAMP-C2 Ras [112] | Mouse | 10 ng/mL | 24 h | WB, FC | ↑ |
Vcap [94] | Human | 100 U/mL | 48 h | FC | ↑ |
↑ Upregulation/increase; = No alteration; FC: flow cytometry; RT-PCR: Real-Time Polymerase Chain Reaction analysis; WB: Western blot analysis.